HK1223852A1 - 睪丸酮凝膠組合物及相關方法 - Google Patents
睪丸酮凝膠組合物及相關方法 Download PDFInfo
- Publication number
- HK1223852A1 HK1223852A1 HK16112308.4A HK16112308A HK1223852A1 HK 1223852 A1 HK1223852 A1 HK 1223852A1 HK 16112308 A HK16112308 A HK 16112308A HK 1223852 A1 HK1223852 A1 HK 1223852A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- gel compositions
- related methods
- testosterone gel
- testosterone
- gel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361915742P | 2013-12-13 | 2013-12-13 | |
| US201361915742P | 2013-12-13 | ||
| US201414177765 | 2014-02-11 | ||
| US14/177,765 US8785426B1 (en) | 2013-12-13 | 2014-02-11 | Testosterone gel compositions and related methods |
| PCT/US2014/069760 WO2015089289A1 (en) | 2013-12-13 | 2014-12-11 | Testosterone gel compositions and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1223852A1 true HK1223852A1 (zh) | 2017-08-11 |
Family
ID=51177812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16112308.4A HK1223852A1 (zh) | 2013-12-13 | 2014-12-11 | 睪丸酮凝膠組合物及相關方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US8785426B1 (zh) |
| EP (1) | EP3079703A4 (zh) |
| AU (1) | AU2014362275A1 (zh) |
| CA (1) | CA2857286C (zh) |
| HK (1) | HK1223852A1 (zh) |
| SG (1) | SG11201604788UA (zh) |
| WO (1) | WO2015089289A1 (zh) |
| ZA (1) | ZA201604587B (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3332787A4 (en) * | 2015-09-30 | 2018-08-01 | Fujifilm Corporation | Transdermally absorbable composition |
| US20200101085A1 (en) * | 2018-09-28 | 2020-04-02 | Joel Studin | Transpore delivery of drugs and uses thereof |
| BE1030538B1 (nl) * | 2022-05-18 | 2023-12-19 | Bogaert Gina Van | Liposomaal preparaat met ingekapselde hormonen, werkwijze voor de productie en gebruik ervan |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731303A (en) | 1985-12-04 | 1998-03-24 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery compositions |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4863970A (en) | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
| US5332577A (en) | 1988-12-27 | 1994-07-26 | Dermamed | Transdermal administration to humans and animals |
| US5152997A (en) | 1990-12-11 | 1992-10-06 | Theratech, Inc. | Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels |
| WO1993025168A1 (en) | 1992-06-11 | 1993-12-23 | Theratech, Inc. | The use of glycerin in moderating transdermal drug delivery |
| US5885565A (en) | 1993-03-19 | 1999-03-23 | Cellegy Pharmaceuticals Inc. | Methods for inducing phase separation of epithelial lipid bilayers |
| US5760096A (en) | 1996-10-18 | 1998-06-02 | Thornfeldt; Carl R. | Potent penetration enhancers |
| US6019997A (en) | 1997-01-09 | 2000-02-01 | Minnesota Mining And Manufacturing | Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents |
| US5908619A (en) | 1997-01-09 | 1999-06-01 | Minnesota Mining And Manufacturing Company | Hydroalcoholic compositions thickened using surfactant/polymer complexes |
| DE69840426D1 (de) | 1997-11-10 | 2009-02-12 | Strakan Int Ltd | Penetrationsfördernde und irritationsvermindernde Systeme mit Testosteron |
| AU1728099A (en) | 1997-12-22 | 1999-07-12 | Alza Corporation | Monoglyceride and ethyl palmitate permeation enhancer compositions |
| KR100684055B1 (ko) | 1998-03-19 | 2007-02-16 | 머크 앤드 캄파니 인코포레이티드 | 생물활성 물질의 방출 조절용 액체 중합체성 조성물 |
| US6733767B2 (en) | 1998-03-19 | 2004-05-11 | Merck & Co., Inc. | Liquid polymeric compositions for controlled release of bioactive substances |
| WO2002011768A1 (en) * | 2000-08-03 | 2002-02-14 | Antares Pharma Ipl Ag | Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
| US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
| US20040198706A1 (en) | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
| US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| CA2746787A1 (en) | 2000-08-30 | 2002-03-07 | Unimed Pharmaceuticals, Llc. | Method of increasing testosterone and related steroid concentrations in women |
| TWI331522B (en) | 2001-06-22 | 2010-10-11 | Cpex Pharmaceuticals Inc | Pharmaceutical composition |
| JP3909812B2 (ja) | 2001-07-19 | 2007-04-25 | 富士フイルム株式会社 | 表示素子及び露光素子 |
| AU2002340120A1 (en) | 2001-10-04 | 2003-04-14 | Cellegy Pharmaceuticals, Inc. | Semisolid topical hormonal compositions and methods for treatment |
| FR2832311B1 (fr) | 2001-11-21 | 2004-04-16 | Besins Int Belgique | Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations |
| FR2834212B1 (fr) | 2001-12-27 | 2004-07-09 | Besins Int Belgique | Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques |
| MY139721A (en) * | 2002-04-19 | 2009-10-30 | Cpex Pharmaceuticals Inc | Pharmaceutical composition |
| JP5160018B2 (ja) | 2002-06-25 | 2013-03-13 | アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッド | 非晶質医薬組成物を用いる経皮送達速度調節 |
| FR2851470B1 (fr) | 2003-02-20 | 2007-11-16 | Besins Int Belgique | Composition pharmaceutique pour administration transdermique ou transmuqueuse |
| EP1663142A2 (en) | 2003-06-23 | 2006-06-07 | MacroChem Corporation | Compositons and methods for topical administration |
| US20070287688A1 (en) | 2003-07-11 | 2007-12-13 | Macro Chem Corporation | Pharmaceutical Compositions for Topical Application |
| DK2450041T3 (en) | 2005-10-12 | 2018-11-19 | Unimed Pharmaceuticals Llc | Enhanced testosterone gel for use in the treatment of hypogonadism |
| US20120022033A1 (en) * | 2010-07-23 | 2012-01-26 | Biosante Pharmaceuticals, Inc. | Methods for decreasing cardiovascular risk in postmenopausal women |
| JO3755B1 (ar) | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
| WO2013130535A1 (en) | 2012-02-27 | 2013-09-06 | Newgen Biopharma Corporation | Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same |
-
2014
- 2014-02-11 US US14/177,765 patent/US8785426B1/en active Active
- 2014-06-17 US US14/307,085 patent/US9295675B2/en active Active
- 2014-07-18 CA CA2857286A patent/CA2857286C/en not_active Expired - Fee Related
- 2014-12-11 HK HK16112308.4A patent/HK1223852A1/zh unknown
- 2014-12-11 WO PCT/US2014/069760 patent/WO2015089289A1/en active Application Filing
- 2014-12-11 EP EP14870202.0A patent/EP3079703A4/en not_active Withdrawn
- 2014-12-11 SG SG11201604788UA patent/SG11201604788UA/en unknown
- 2014-12-11 AU AU2014362275A patent/AU2014362275A1/en not_active Abandoned
-
2016
- 2016-03-25 US US15/081,402 patent/US9662340B2/en active Active
- 2016-07-06 ZA ZA2016/04587A patent/ZA201604587B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2857286A1 (en) | 2014-11-21 |
| US20150164913A1 (en) | 2015-06-18 |
| US20160310508A1 (en) | 2016-10-27 |
| ZA201604587B (en) | 2017-11-29 |
| AU2014362275A1 (en) | 2016-07-21 |
| US9662340B2 (en) | 2017-05-30 |
| SG11201604788UA (en) | 2016-07-28 |
| EP3079703A1 (en) | 2016-10-19 |
| US8785426B1 (en) | 2014-07-22 |
| WO2015089289A1 (en) | 2015-06-18 |
| US9295675B2 (en) | 2016-03-29 |
| EP3079703A4 (en) | 2017-07-12 |
| CA2857286C (en) | 2016-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273592A (en) | A multispecific antigen-binding molecule that has the function-changing activity of a cofactor for blood coagulation factor viii (fviii), and a pharmaceutical formulation containing the molecule as an active ingredient | |
| MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
| EP3016653A4 (en) | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof | |
| MX2016016666A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
| MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| WO2015023649A3 (en) | Peptides for enhancing transdermal delivery | |
| BR112014021531A8 (pt) | composto, composição farmacêutica e usos dos mesmos | |
| EA201492011A1 (ru) | Безводные фармацевтические составы для местного применения | |
| EP3714887A4 (en) | PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION AND RELATED PREPARATION PROCESS | |
| EP3034082A4 (en) | Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients | |
| EP3093023A4 (en) | Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient | |
| WO2015056094A3 (en) | Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent | |
| EP3613419A4 (en) | PHARMACEUTICAL COMPOSITION WITH INDIRUBY DERIVATIVE AS THE ACTIVE SUBSTANCE | |
| WO2014121764A3 (en) | 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions | |
| MY168212A (en) | A new therapeutical composition containing apomorphine as active ingredient | |
| EP3480186A4 (en) | NOVEL ARYLETHANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THIS DERIVATIVE AS ACTIVE INGREDIENT | |
| WO2014121048A3 (en) | Topical compositions and methods for making and using same | |
| MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
| MX368268B (es) | Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih). | |
| WO2014122460A3 (en) | Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes | |
| WO2015001163A3 (es) | Nanopartículas lipídicas para la cicatrización de heridas | |
| MX2015001387A (es) | Formulacion transdermica que contienen inhibidores de ciclooxigenasas (cox). | |
| MX2014014579A (es) | Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide. | |
| WO2014166836A8 (en) | Growth hormone compound formulation |